Quick Answer
Stoke Therapeutics, Inc. reported Total Assets of $418.43 million for fiscal year 2025.
Stoke Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $418.43M | +54.1% |
| 2024 | $271.56M | +18.9% |
| 2023 | $228.34M | -10.8% |
| 2022 | $256.07M | +7.2% |
| 2021 | $238.87M | -19.8% |
| 2020 | $297.93M | +30.2% |
| 2019 | $228.75M | +112.7% |
| 2018 | $107.54M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $360.26M | +22.8% | -6.3% |
| June 30, 2025 | $384.51M | +24.9% | -5.5% |
| March 31, 2025 | $406.89M | +98.3% | +49.8% |
| December 31, 2024 | $271.56M | +18.9% | -7.4% |
| September 30, 2024 | $293.32M | +22.3% | -4.7% |
| June 30, 2024 | $307.76M | +19.8% | +50.0% |
| March 31, 2024 | $205.18M | -27.2% | -10.1% |
| December 31, 2023 | $228.34M | -10.8% | -4.8% |
- Stoke Therapeutics, Inc. showed an increase of +54.1% in Total Assets compared to the prior fiscal year.
- Over the 2018–2025 period, Stoke Therapeutics, Inc.’s total assets has grown by 289.1% (from $107.54 million to $418.43 million).
- The most recent figure is from Stoke Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: